# Filing Detail

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-26-036970
Filing Date
2026-03-31
Accepted
2026-03-31 09:29:19
Documents
87
Period of Report
2025-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | ANNUAL REPORT | ea0283072-20f_neurosense.htm iXBRL | 20-F | 2424330
2 | AMENDED AND RESTATED ARTICLES OF ASSOCIATION | ea028307201ex1-1.htm | EX-1.1 | 285028
3 | DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF | ea028307201ex2-1.htm | EX-2.1 | 55435
4 | CERTIFICATION | ea028307201ex12-1.htm | EX-12.1 | 9615
5 | CERTIFICATION | ea028307201ex12-2.htm | EX-12.2 | 9834
6 | CERTIFICATION | ea028307201ex13-1.htm | EX-13.1 | 3284
7 | CERTIFICATION | ea028307201ex13-2.htm | EX-13.2 | 3403
8 | CONSENT OF SOMEKH CHAIKIN (MEMBER FIRM OF KPMG INTERNATIONAL), INDEPENDENT REGIS | ea028307201ex15-1.htm | EX-15.1 | 2021
9 | GRAPHIC | ea028307201_img1.jpg | GRAPHIC | 13557
| Complete submission text file | 0001213900-26-036970.txt |  | 8735156

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
10 | XBRL SCHEMA FILE | nrsn-20251231.xsd | EX-101.SCH | 58625
11 | XBRL CALCULATION FILE | nrsn-20251231_cal.xml | EX-101.CAL | 39671
12 | XBRL DEFINITION FILE | nrsn-20251231_def.xml | EX-101.DEF | 292050
13 | XBRL LABEL FILE | nrsn-20251231_lab.xml | EX-101.LAB | 535290
14 | XBRL PRESENTATION FILE | nrsn-20251231_pre.xml | EX-101.PRE | 301906
91 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0283072-20f_neurosense_htm.xml | XML | 968731

Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-41084 | Film No.: 26817900
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)